Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Practice Guidelines
    • Featured Practice Guidelines
    • Inflammatory bowel...

    Inflammatory bowel disease - Standard Treatment Guidelines

    Written by supriya kashyap kashyap Published On 2016-11-29T09:14:58+05:30  |  Updated On 29 Nov 2016 9:14 AM IST
    Inflammatory bowel disease - Standard Treatment Guidelines

    Inflammatory bowel disease (IBD) represents a group of idiopathic chronic inflammatory intestinal conditions. The two main disease categories included are Crohn’s disease (CD) and ulcerative colitis (UC), with both overlapping and distinct clinical and pathological features. In addition the spectrum also comprises two categories ; IBD unclassified and indeterminate colitis. The pathogenesis of IBD is still under investigation. The most simplified view is that intestinal injury results due to aberrant immune response to commensal bacteria in a background of genetic predisposition.


    Ministry of Health and Family Welfare has come out with the Standard Treatment Guidelines for Inflammatory bowel disease. Following are its major recommendations.



    Case definition:



    • Ulcerative colitis: Ulcerative colitis is a chronic disorder of unknown etiology in which a part or the whole of the mucosa of the colon becomes diffusely inflamed and ulcerated. Rectum is involved in a vast majority of the cases.

    • Crohn’s Disease: A chronic granulomatous disease which can affect any part of GI tract in a discontinuous, asymmetric manner. Unlike Ulcerative colitis which is a mucosal disease, Crohn’s disease is a transmural disease.

    • IBD unclassified: Categorization is not possible after clinical, radiological, endoscopic and histological features

    • Indeterminate colitis: Categorization is not possible even after evaluation of resected specimen.


    Incidence of The Condition In Our Country


    The epidemiological studies from this region are being made available it is clear that the incidence and prevalence rates of IBD in Asia–Pacific region are low compared with Europe and North America. They are however, increasing rapidly.


    There are substantial variations in the incidence and prevalence rates of IBD in various ethnic groups in Asia. The highest incidence rates are recorded from India, Japan and the Middle East and there exists a genetic predisposition of South Asians (Indians, Pakistanis and Bangladeshis) to ulcerative colitis (UC). In a study done in 2001 from Ludhiana in Punjab, the crude prevalence rate was 44.3/105 . The incidence was calculated after a second visit to the same area one year later. The crude incidence rate was 6.02/105 . The incidence rate of UC in India is higher than in Asian countries like Japan (1.95/105 ) and Korea (1.23/105 ). There is no population-based study on Crohn’s disease (CD) in India, however, the accepted perception is that the incidence of CD is rapidly rising in India. The peak age of incidence of CD is the third decade of life, with a decreasing incidence rate with age. The incidence rate in UC is quite stable between the third and seventh decades.



    Differential Diagnosis


    The main differential diagnosis of Ulcerative colitis and Crohn’s disease are :






































    Ulcerative colitisCrohn’s disease
    Acute self limiting colitisIntestinal Tuberculosis
    Amoebic colitisAcute self limiting colitis
    Crohn’s DiseaseAmoebic colitis
    HIV enteropathyUlcerative colitis
    Behcet’s disease
    NSAID enteropathy
    HIV enteropathy

    Prevention And Counselling


    IBD is an autoimmune disease, and environmental factors which can trigger an episode have not been identified, hence primary prevention strategy is not possible. There is a family history in 5% of IBD patients.



    Optimal Diagnostic Criteria, Investigation, Treatment & Referral Criteria


    *Situation 1: At Secondary Hospital/ Non-Metro situation: Optimal Standards of Treatment in Situations where technology and resources are limited


    There is no gold standard test available to make a diagnosis of IBD. A diagnosis of ulcerative colitis or Crohn’s disease is made on the basis of compatible clinical history, examination, imaging, endoscopy and histology findings.


    Clinical Diagnosis:



    History


    The most important features are the chronic duration of symptoms and the frequent remissions and relapses which characterize IBD and help in distinguishing from other infectious diseases affecting the large and small bowel.


    Ulcerative colitis


    1. Diarrhea : Large bowel diarrhea which is daytime or nocturnal


    2. LGI bleed : Blood may be mixed with stool and at times separate from the stools


    3. Rectal symptoms: tenesmus, urgency , frequency of stools


    4. Abdominal pain and fever in case of severe disease


    5. Symptoms are limited to large bowel



    Crohn’s disease(CD)


    Symptoms depend upon the site of involvement. In CD , any part of bowel from esophagus to anal canal may be involved .


    Small Intestinal involvement / Ileocolonic involvement :


    1. Abdominal Pain


    2. Symptoms suggestive of recurrent partial intestinal obstruction may be present


    3. Chronic diarrhea


    4. Fever, anorexia, weight loss


    Large bowel involvement :


    1. Chronic diarrhea


    2. Hematochezia


    3. Peri anal disease


    4. Fever, weight loss


    5. Abdominal pain


    Upper GI involvement


    1. Dysphagia, odynophagia


    2. Epigastric pain


    3. Symptoms suggestive of gastric outlet obstruction


    Extraintestinal manifestations (EIM) : Arthritis is the most common EIM and is observed in 15-20% of cases. Other extraintestinal complications include ankylosing spondylitis, pyodermagangrenosum, erythema nodosum, iritis, uveitis, episcleritis, and primary sclerosing cholangitis.


    Complications include :


    1. Hemorrhage: profuse bleeding from ulcers in UC. Bleeding is less common in CD. Massive bleeding in CD is more often seen from ileal ulceration than colitis.


    2. Strictures, bowel perforation and Intra-abdominal abscesses in CD.


    3. Fistulas and perianal disease in CD


    4. Colorectal cancer: Significantly increased risk of colon cancer in UC after 8 years of diagnosis; the risk is lower in CD as compared to UC.



    Investigations:


    Primary and secondary care settings :




    • Stool for ova and cysts

    • Haemogram and Serum albumin

    • Sigmoidoscopy (if available)

    • Barium enema for ulcerative colitis

    • In India, at present, a suspected case of Crohn’s disease should always be referred to a tertiary care hospital before initiating therapy. This is so as to rule out intestinal tuberculosis which closely mimics Crohn’s disease.


    Referral Hospitals:


    Stool examination:


    i ) Parasites


    ii)Clostridium difficile(should be considered even in absence of antecedent antibiotics).


    Blood tests :


    i) Haemoglobin, ESR , serum albumin , Human immunodeficiency virus (HIV)


    ii) Perinuclear antineutrophil cytoplasmic antibody (p-ANCA) and antiSaccharomyces cerevisiae antibodies (ASCA): need not be done


    iii) Celiac serology




    • Monteux skin test

    • Chest X ray

    • Sigmoidoscopy / Colonoscopy An endoscopic examination is necessary


    a) to establish the diagnosis


    b) to assess severity of disease


    c) to take targeted mucosal biopsies . In cases with severe activity, a full length colonoscopy is not indicated as there is a high risk of perforation.


    Ulcerative colitis:


    An ileocolonoscopy is indicated to establish the extent of disease


    Crohn’s Disease: Endoscopic procedures required include : 1) ileocolonoscopy 2) UGI endoscopy ( especially in pediatric cases) 3)Capsule endoscopy/ double balloon enteroscopy if small bowel involvement suspected.




    • Histology


    Multiple mucosal biopsies should be taken from inflamed areas. Features suggestive of ulcerative colitis include crypt architectural destruction, crypt abscesses, goblet cell depletion, paneth cell metaplasia, basal plasmocytosis. In Crohn’s disease non caseating granulomas may be seen in 30% of cases




    • Imaging



    1. Abdominal X ray: In severe UC or CD where perforation or toxic mega colon is suspected. In CD, if intestinal obstruction is suspected.

    2. Contrast enhanced computed tomography ( Enteroclysis/Enterography) : In cases with CD i) to evaluate small intestinal involvement ii) to differentiate from intestinal tuberculosis

    3. Barium meal follow through: If facilities for CT (enteroclysis) are not present.



    • These investigations not only help in diagnosing the disease but also help in determining the extent and severity of the disease . The tables below show the classification for extent and severity of UC and CD.


    Table 1: Disease extent in Ulcerative colitis:


























    Extent Disease Description
    E1Ulcerative proctitisInvolvement limited to rectum
    E2Left sided

    UC (distal colitis)
    Involvement distal to the splenic flexure
    E3Extensive

    UC (Pancolitis)
    Involvement extends proximal to the splenic flexure

    Table 2: Disease activity in Crohn’s Disease (ACG classification)
















    Mild ( corresponds to CDAI < 150)Moderate ( corresponds to CDAI 150-220)Severe ( corresponds to CDAI 150>450)
    Ambulatory, eating

    <10% weight loss

    No features of

    Dehydration

    Obstruction, fever,

    Abdominal mass or

    Tenderness

    CRP > upper limit
    Intermittent voming,

    Abdominal pain, > 10%

    Weight loss

    No feature of

    Dehydration

    Obstruction, fever,

    Abdominal mass or

    Tenderness

    CRP > upper limit
    BMI < 18, cachexia,

    Dehydration

    Evidence of

    Obstruction or

    Abscess

    Persistent symtoms

    Despite intensive Rx

    Table 3 : Montreal Classification of Crohn’s disease phenotype


















    AgeA1 : < 16 years

    A2 : 17-40 years

    A3 : > 40 years
    LocationL1 : Ileal

    L2 : Colonic

    L3 : Isolated upper GI disease*
    BehaviourB1 : Non structuring non penetrating disease

    B2 : Structuring disease

    B3 : Penetrating disease

    P : perianal disease modifier #

    In addition , these investigations also help in 1) differentiating Ulcerative colitis from Crohn’s disease 2) Intestinal tuberculosis from Crohn’s disease as shown in the tables below


    Table 4 : Features for differentiating between ulcerative colitis (UC) and Crohn’s disease (CD) (adapted from World Gastroenterology Organisation Global Guidelines June 2009)


























    Typical UC featuresTypical UC features
    ClinicalFrequent small-Volume diarrhea with urgency

    Predominantly bloody diarrhea
    Diarrhea accompanied by abdominal pain and malnutrition

    Stomatitis

    Abdominal mass

    Perianal lesions
    Endoscopic and radiologicalDiffuse superficial colonic inflammation

    Involvement of rectum, but this can be patchy

    Shallow erosions and ulcers

    Spontaneous bleeding
    Discontinuous transmural asymmetric lesions

    Mainly involving ileum and right sided colon

    Cobblestone appearance

    Longitudinal ulcer

    Deep fissures
    HistopathologicalDiffuse inflammation in mucosa or submucosa

    Crypt architecture distortion
    Granulomatous inflammation

    Fissures or aphthous ulcers can be seen: often transmural inflammation

    IBD management should be based on:




    • UC vs. CD (although this is less important for early aspects of treatment)

    • Disease location and phenotype

    • Severity


    The goals of treatment are to:




    • Maintain steroid-free remissions (decreasing the frequency and severity of recurrences and reliance on steroids)

    • Prevent complications hospitalization and surgery


    Treatment include two phases




    • Induction of remission

    • Maintenance of remission


    Ulcerative colitis :


    Disease extent: Proctitis and Proctosigmoiditis




    • Inducing Remission


    Proctitis : 5ASA suppositories ; Optimal dose : 1gm/day


    Proctosigmoiditis : 5ASA enemas : 2-4 gm/


    If no response within 4 week


    Use of topical glucocorticoids


    If still no response :


    Use of hydrocortisone rectal drip: 200mg/200ml/1-2 hrs




    • Maintaining remission


    Oral 5 ASA in a dose of 1600-2400 mg daily may be used with or without topical therapy


    If disease extent is left sided colitis/pancolitis, then the treatment may be planned as in the table below:


    A. For Induction of remission depending upon the severity of disease


























    Mild to Moderate:Severe :Fulminant :
    SZA : 4-6 gm/day

    5ASA : 4gm/day
    Oral steroidsHospitalization

    IV steroids

    Intensive Therapy

    Surgery
    No clinical response:

    Perdnisolone :

    40-60 mg/day
    No response :

    Hospitalization

    IV steroids

    Intensive Therapy
    Steroid tapering :

    Very gradual

    Over 3-4 months


    B. For maintenance of remission : Use of 5 ASA alone or 5ASA and azathioprine in patients


    who require frequent steroids



    Management guidelines in Crohn’s Disease ( as in the table below)















































    Inflammatory CD

    ( B1 phenotype)
    Mild to moderateInduction regime

    SSZ : left colon

    Budesonide : ileocolon
    Remission :

    Azathioprine

    Methotrexate
    Moderate with systemic

    Symptoms

    Severe

    Small bowel extensive disease
    Induction regime

    Prednisolone

    IV Hydrocortisone
    Remission :

    Azathioprine

    Methotrexate
    Introduction of InfliximabCorticosteroid dependent

    Corticosteroid refractory

    2 courses of steroids/year

    Risk factors for Top Down rx group
    Remission :

    IFX +

    Azathioprine

    Not Methotrexate
    Fistulizing Disease

    (B3 phenotype)
    Perianal : Simple vs complexAntibiotics, azathioprine Infliximab , Surgery
    Non perianalSurgery
    Stricturing Disease

    (B2 phenotype)
    Steroids/balloon dilatation/surgery/? Infliximab

    Referral criteria:


    Criteria for surgery referral :




    • Toxic megacolon

    • Perforation peritonitis

    • Severe bleed

    • Refractory to medical therapy

    • Stricturing Crohn’s disease


    Standard Operating procedure


    a. In Patient : Patients with severe disease not responding to oral steroids


    b. Out Patient : Patients with mild to moderate disease or patients in remission on follow up


    c. Day Care : Any patient requiring infliximab maintenance infusion



    WHO DOES WHAT? and TIMELINES


    a. Doctor: Diagnose and strategise therapy


    b. Nurse : Assist in administering drugs


    c. Technician : Assist in endoscopy and imaging investigations



    Guidelines by The Ministry of Health and Family Welfare :


    developed by Dr Vineet Ahuja Deptt of Gastroenterology, All India Institute of Medical Sciences, New Delhi
    Crohn's diseaseIBDinflammatory bowel diseaseMinistry of Health and Family WelfareStandard Treatment Guidelinesulcerative colitis.

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok